Half of MS patients use cannabis medicinally, but neurologists have limited prescribing guidance
Around half of MS patients have used cannabis medicinally and would endorse legalization, yet clinicians lack clear guidance on prescribing, and access to pharmaceutical-grade products remains highly restricted.
Quick Facts
What This Study Found
About half of MS patients report previous or current medicinal cannabis use. Despite governments worldwide relaxing regulations, questions remain about how clinicians should prescribe or recommend products. Access to pharmaceutical-grade cannabis remains highly restricted even where legal.
Key Numbers
Approximately 50% of MS patients report medicinal cannabis use. Many governments relaxing regulations worldwide. Pharmaceutical-grade product access remains highly restricted.
How They Did This
Clinical review for practicing adult neurologists, summarizing what is known about cannabis use in multiple sclerosis and the practical challenges of integrating cannabis into MS care.
Why This Research Matters
MS patients are already using cannabis in large numbers. Neurologists need practical guidance that acknowledges this reality while navigating the gap between patient demand and available evidence.
The Bigger Picture
The disconnect between patient cannabis use (50%) and clinical guidance for neurologists reflects a broader healthcare failure. Patients are self-medicating with unregulated products while the medical system struggles to provide evidence-based alternatives.
What This Study Doesn't Tell Us
Clinical review rather than systematic review. General overview without detailed efficacy analysis. Prescribing guidance remains vague by necessity due to limited evidence.
Questions This Raises
- ?What standardized protocols would help neurologists recommend cannabis safely?
- ?Could MS-specific cannabis guidelines reduce harms from self-medication?
- ?Which cannabis products and routes are most appropriate for specific MS symptoms?
Trust & Context
- Key Stat:
- ~50% of MS patients use cannabis medicinally; neurologists lack prescribing guidance
- Evidence Grade:
- Moderate: clinical review from a specialist neurology journal addressing practical care gaps.
- Study Age:
- Published in 2019.
- Original Title:
- Cannabis and multiple sclerosis.
- Published In:
- Practical neurology, 19(4), 310-315 (2019)
- Authors:
- Ingram, Gillian, Pearson, Owen R
- Database ID:
- RTHC-02084
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Do MS patients commonly use cannabis?
Yes. This review estimates about half of MS patients have used cannabis for medicinal purposes and would support legalization. Licensed treatments only partially control many MS symptoms, driving patients to seek alternatives.
Can neurologists prescribe cannabis for MS?
The situation varies by jurisdiction, but access to pharmaceutical-grade cannabis remains highly restricted everywhere. Many neurologists face unanswered questions about what to recommend, how to dose, and which products to use.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02084APA
Ingram, Gillian; Pearson, Owen R. (2019). Cannabis and multiple sclerosis.. Practical neurology, 19(4), 310-315. https://doi.org/10.1136/practneurol-2018-002137
MLA
Ingram, Gillian, et al. "Cannabis and multiple sclerosis.." Practical neurology, 2019. https://doi.org/10.1136/practneurol-2018-002137
RethinkTHC
RethinkTHC Research Database. "Cannabis and multiple sclerosis." RTHC-02084. Retrieved from https://rethinkthc.com/research/ingram-2019-cannabis-and-multiple-sclerosis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.